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Acute Coronary Syndromes (ACS) are triggered by the occlusion of a coronary 
artery, usually due to the thrombosis of an atherosclerotic plaque. The study of the 
mechanisms that lead to the plaque thrombosis has been one of the hot spots in 
cardiovascular research during the last years. A screening for biomarkers in the blood 
of ACS patients using proteomic tools could provide useful diagnostic and therapeutic 
information. We have performed a comparative study of plasma from ACS patients 
combining immunoaffinity depletion with 2-dimensional difference gel electrophoresis 
(2D-DIGE) and identification by mass spectrometry.
Depleted plasma samples from 28 patients with ACS at day 0, 4, 90 and 180, were 
compared to samples from 10 stable coronary artery disease (CAD) patients and 10 
healthy volunteers, matched for age and sex. DeCyder software revealed statistically 
significant variations of 47 protein spots in depleted plasma samples from ACS and 
stable CAD patients in comparison with healthy subjects. The number of differentially 
expressed spots tended to increase along time, conversely to that observed for circulating 
monocytes. The identified proteins were involved in different physiological processes, 
some of whom may play a role in the pathophysiology of the atherotrombotic disease.
We have also studied the effect of intensive treatment with statins in comparison 
with moderate treatment, assigning patients to receive either 80 mg/d atorvastatin 
(ATV) or standard therapy during two months after ACS. Expression levels of 15 spots 
were affected by both treatments, while 14 different spots were normalized by ATV 
with respect to standard therapy and 4 more spots were only altered by ATV.
Further validation of these findings in larger populations would prove the usefulness 
of these proteins as novel biomarkers of ACS. These results might help to enrich the 
current knowledge of molecular mechanisms involved in ACS and improve the existing 
diagnostic tools.
